Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | GSK1070916 | GDSC1000 | pan-cancer | AAC | -0.011 | 0.7 |
mRNA | GSK-J4 | CTRPv2 | pan-cancer | AAC | 0.037 | 0.7 |
mRNA | XMD11-85h | GDSC1000 | pan-cancer | AAC | 0.016 | 0.7 |
mRNA | BRD-K51490254 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.7 |
mRNA | compound 1B | CTRPv2 | pan-cancer | AAC | -0.013 | 0.7 |
mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.012 | 0.7 |
mRNA | PF-573228 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.7 |
mRNA | JQ-1 | CTRPv2 | pan-cancer | AAC | 0.01 | 0.7 |
mRNA | BRD-K71935468 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.7 |
mRNA | JW-7-24-1 | GDSC1000 | pan-cancer | AAC | 0.0095 | 0.7 |